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Objective: The objective of this analysis is to study safety and efficacy of BioMatrix, Biolimus
A9-eluting stent in diabetic patients.
Background: Patients with diabetes mellitus (DM) are at high risk for restenosis, myocardial
infarction, and cardiac mortality after coronary stenting. Long-term safety of drug-eluting
stents (DES) in DM is relatively uncertain. Interim report of the BioMatrix dedicated diabetic
registry showed significantly lowered MACE rates. Thus, a diabetic cohort was analyzed
from the all comers Biomatrix registry to confirm its safety and efficacy at large.
Methods: In the BioMatrix all comers registry, 1189 patients were enrolled prospectively
between December 2008 and February 2012. This subgroup analysis consists of 485 diabetic
patients from this registry. We analyzed the incidence of Major Adverse Cardiac Events5.
ndia.com (H. Rangnekar).
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all comers registry in India, Indian Heart(MACE) and Stent Thrombosis (ST) at 1, 6, and 12 months with an extended follow-up of
two years. At the time of this analysis, all patients had completed two-year follow-up.
Results: The mean age was 58.38 ± 10.03 years (range 31e87), average LVEF was
50.98 ± 11.87% (range 19e95). The mean age was 58.38 ± 10.03 years. 14.4% patients were
insulin dependent (IDDM). 58.7% were hypertensive, 10.7% had family history of CAD, 20%
had hypercholesterolemia and 7.4% had suffered previously with MI, 64.53% presented
with acute coronary syndrome. STEMI patients comprised of 34.02%. 15.67% had total oc-
clusion. 10.51% were patients with Multi Vessel Disease At two-year follow-up, very low
MACE rate of 0.62% was observed. There was only a single case of probable ST.
Conclusion: This analysis continues to confirm clinical safety and efficacy of BioMatrix stent
in diabetic patients along with additional risk factors. The two-year result shows that
BioMatrix stent is a suitable alternative as compared to contemporary DESs which are
currently available in the market for simple as well complex disease.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Introduction
Diabetes mellitus (DM), accounting for more than 25% of all
percutaneous coronary interventions (PCI)1,2 is associated with
an increasedriskofadverseclinicaloutcomesafterPCI.3e5Drug-
eluting stents (DES) have revolutionized the field of interven-
tional cardiology by dramatically improving clinical and angio-
graphic outcomes relative to baremetal stents (BMS) in patients
with andwithout diabetes.6,7 However, there has been diffused
concern about the safety profile, the recent meta-analysis has
revealed that thrombosis doesnot occurmore frequently inDES
than in BMS.8e10 Available information on the efficacy and
safety of DES and BMS in diabetic patients remains scarce.
The prevalence of CHD rises from 2% to 4% in the general
population to as high as 55% among adult diabetic patients.11
Diabetesmellitus is an independent risk factor for CVD in both
men and women. Cardiovascular risk factors and comorbid-
ities that negatively impact cardiovascular outcomes aremore
prevalent in DM patients.12
In a population-based autopsy study, coronary arteries
were examined at 5-mm intervals with a semiquantitive
grading system.13 High-grade atherosclerosis was defined as
grade 3 (50%e75%) left main stem disease or grade 4 (>75%)
disease for other arteries. Coronary atherosclerosis was found
in 49% of diabetic and 33% of non-diabetic decedents. These
findings revealed a high prevalence of subclinical atheroscle-
rosis in diabetic subjects without a clinical history of CHD.
The proportion of coronary disease patients with diabetes
varies across countries, but approximately one-fifth of clinical
trial (18%)14andregistrypatients (15.1e21.4%)15aredocumented
asknowndiabetespatients. Indiastandsoutasananomalywith
30.4%, 36% and 39.1%16 of CHD patients reporting known dia-
betes in national and international prospective registries.
Because restenosis can bemore aggressive in patients with
DM, it is important to characterize whether these results are
maintained in this higher-risk subgroup of patients undergo-
ing percutaneous coronary intervention (PCI) with Biolimus
A9-eluting stent (BES). We therefore sought to examine dia-
betic subset outcomes in BioMatrix PMR registry stratified by
diabetic subgroup. This stratified analysis includes two-year
follow-up result in terms of MACE and ST.K, et al., A two year anal
Journal (2014), http://dx2. Method
In the BioMatrix all comers registry, 1189 patients were
enrolled prospectively between December 2008 and February
2012. A subgroup analysis of 485 diabetic patients from reg-
istry was done. Primary endpoint of this registry was Major
Adverse Cardiac Events (MACE) defined as composite of car-
diac death, myocardial infarction (MI), or target vessel revas-
cularization (TVR)within the study population at 12months of
follow-up. Secondary outcomes were stent thrombosis (ST) at
1, 6 and 12 months and 2 years. The inclusion criteria, were
patients eligible for PCI with lesions suitable for stent im-
plantation with age18 years, presence of 1 coronary artery
stenoses in a native coronary artery or saphenous bypass graft
or radial vein graft from 2.25 mm to 4.0 mm in diameter that
can be covered with one or multiple stents with no limitation
to the number of treated lesions, number of treated vessels or
lesion length. Those patients who received additional stent
other than BioMatrix were excluded. The Ethics Committee
approval was sought and informed consent for participation
was obtained from each willing and eligible patient before or
after PCI who underwent implantation of Biolimus A9-eluting
stent according to the standard procedure.
The baseline data of diabetic subgroup were analyzed from
registry patient's data. Implantation of BioMatrix, Biolimus A9-
eluting stent in the target lesion during the index procedure
was mandatory in registry. The appropriate length and diam-
eter of the stents to be implanted ensuring complete coverage
of the lesion were chosen by visual estimate. The stent length
ranged between 8 mm and 28 mm (20.88 ± 5.9), with long
length stenting in 27.01% patients. Multiple stents were
implanted in 51 (10.51%) patients. At least 2 mm overlap was
achieved if more than one stent was implanted. Treatment of
multiple target vessels (within the same procedure) and staged
procedures which occur within 90 days of the initial implant
procedure were allowed. All postoperative medical manage-
ment, including dual antiplatelet therapy, was prescribed ac-
cording to usual local practice at the discretion of the
cardiologist. Data analyzed includes demographic informa-
tion, cardiovascular history, comorbidity, lesion and procedure
characteristics, and antiplatelet regimens. Patients wereysis of Diabetic subset ‘e-BioMatrix’ prospective, multicentric,
.doi.org/10.1016/j.ihj.2014.08.011
Table 2 e Medical history of baseline characteristics in
485 subjects.
Baseline characteristics n (485) %
Diabetes mellitus 485 100
IDDM 70 14.4
NIDDM 385 85.6
Current smoker 81 16.7
Renal insufficiency at screening 9 1.8
Hypercholesterolemia 97 20
Hypertension 285 58.7
Family history of CAD 52 10.7
Congestive heart failure 24 4.9
Previous myocardial infarction 36 7.4
Previous CABG 16 3.3
Previous PCI(s) 26 5.3
Peripheral vascular disease 3 0.62
Stroke 9 1.85
Number of lesions treated 592
Number of stents 642
Male 389 80.2
Female 96 19.59
Lesion stent length 131 27.01
Lesion stent diameter 19 3.91
Total occlusion 76 15.67
Bifurcation 03 0.61
Single vessel (SVD) 445 91.75
Multi vessel (MVD) 51 10.51
Acute coronary syndrome 313 64.53
STEMI 165 34.02
Asymptomatic 39 8.04
Silent ischemia only 55 11.34
Stable angina 72 14.84
Anginal LVEF (%) 455
LVEF <40% 279 57.52
i n d i a n h e a r t j o u r n a l x x x ( 2 0 1 4 ) 1e6 3followed at 1, 6, 12 and at 24 months by on-site visit with the
study physicians or by telephonic communication. Interven-
tional cardiologists selected to participate as investigators in
this registry were qualified and/or board certified. The study
data was verified on-site by the study monitoring group for
consistency with source data and to ensure compliance with
the protocol as well as with Indian regulatory guidelines.
The technical details of the drug-eluting coronary stent
system (BioMatrix DES) is comprised of two key components:
the stent (which includes the drug as BiolimusA9 incorporated
into a polymer coating), and the delivery catheter. A balloon
expandable 316L stainless steel stent with polymer coating
containing Biolimus A9 drug is pre-mounted onto a high
pressure, semi-compliant rapid exchange balloon delivery
system available in six and nine cell models. The delivery
catheter has two radiopaque markers, which fluoroscopically
mark the ends of the stent to facilitate proper stent placement.
The nominal dosage of Biolimus A9 for the BioMatrix stent
ranges from 133 mg to 451 mg depending on stent length. The
biodegradable polymer is polylactic acid (PLA), which has been
widely used in a variety of medical applications, including
orthopedic and dental devices and implants. BioMatrix is
Biosensors' DES having abluminally coated biodegradable
polymer. Its abluminal coating (coating only to outer surface)
is absorbed after 6e9 months and turns the DES into a BMS. It
has an advantage of proven safety of a DES with an abluminal
biodegradable polymer, the proven efficacy of BA9 and of an
advanced stent design. As this DES virtually becomes a BMS
after 6e9 months, long-term safety to the patients is ensured
and also there is no polymer present, no drug present after 6e9
months, incidence of ST falls considerably.
An independent clinical events committee adjudicated all
MACEs and other serious adverse events developing in the
patient population. The committee arbitrated all MACE, other
SAE and ST by a systematic review of the data collection forms
and by review of the source documents, electrocardiograms,
and angiograms in case of suspected stent thrombosis and
MACE. All statistical analyses for this subgroup were per-
formedwithSPSS (Version16.0). Standard descriptive statistics
were used for baseline, lesion, and procedural characteristics
and for clinical results for all patients. Continuous variables
were presented as mean ± SD and range, and categorical var-
iables were presented as numbers and percentages. Descrip-
tive data of the patient population and serious adverse events
were compiled as per protocol specified time intervals.3. Results
485 diabetic patients' data were analyzed from all comers
BioMatrix registry. Subject age group distribution is describedTable 1 e Age group distribution of 485 study subjects.
Age group n (485) %
20e40 22 4.5
41e60 270 55.6
61e80 184 37.9
80 & above 09 1.6
Total 485 100
Please cite this article in press as: Goyal BK, et al., A two year analy
all comers registry in India, Indian Heart Journal (2014), http://dxin Table 1. 80.20% patients were males (Table 2). The mean
age was 58.38 ± 10.03 years (range 31e87). Though the syntax
score was not calculated, the profile of patients was complex.
It was evident with following mentioned figures. 14.4% pa-
tients were insulin dependent (IDDM). 58.7% were hyperten-
sive, 10.7% had family history of CAD, 20% had
hypercholesterolemia and 7.4% had suffered previously with
MI, 64.53% presented with acute coronary syndrome. STEMI
patients comprised of 34.02%. 15.67% had total occlusion.
Multiple vessel intervention was performed in 10.51% of pa-
tients, Patients' baseline characteristics were as per listed in
Table 2. Most of the lesions were located in the left anterior
descending artery (56.7%) (Table 3). The angiographic LVEF
(%) was 50.98 ± 11.87% (range 15e95). 23.71% had angio-
graphic LVEF 40% (Table 4). The patients included were
compliant with the eligibility criteria specified in the protocol.
A total of 642 BioMatrix DES (1.32 stents/patient) were
implanted during the index procedure, to treat a total ofTable 3 e Total percentage of lesion segments (n ¼ 485).
Lesion segment n %
RCA 106 21.85
LAD 275 56.70
LCx 84 17.32
Left Main 11 2.26
Venous graft bypass 2 0.41
sis of Diabetic subset ‘e-BioMatrix’ prospective, multicentric,
.doi.org/10.1016/j.ihj.2014.08.011
Table 4 e Descriptive statistics (n ¼ 485).
Stent details n Minimum Maximum Mean Std. deviation
Age (years) 484 31 87 58.38 10.03
Number of lesions treated 592 01 04
Number of stents 642 01 04
Anginal LVEF (%) 455 19 95 50.98 11.87
Table 5 e Parameters of lesion stent.
Parameters Objectives n %
Lesion stent length Long length (28 mm) 131 27.01
Lesion stent diameter Small vessel (2.25 mm) 19 3.91
i n d i a n h e a r t j o u r n a l x x x ( 2 0 1 4 ) 1e64592 lesions with a minimum of 1 and maximum of 4 stents
(Table 4).
Out of 485 patients, 3.91% had vessel diameter 2.25 mm
and 27.01% had lesion length of atleast 25 mm (Table 5).
Non-hierarchy approach was used for counting of MACE.
MACE rate of 0.62%was observed (Table 6). There were 2 cases
of MI and one case of cardiac death. There was not a single
case of justified TVR observed in this diabetic subgroup.
Probable late stent thrombosis (as per ARC definitions) was
presented in a single patient (Table 7), having acute AWMI
after one year of enrollment. The check-angio of this patient
revealed triple vessel disease with focal instent stenosis,
thereby was managed medically and was advised for CABG.
There was no case of definite or possible ST presented.4. Discussion
It is nowwell established that diabetics has unacceptably high
rates of restenosis (60%) after coronary POBA16e18 and more
recent studies have shown dramatically higher rates of
occlusive restenosis (13%e14%) in diabetics than in non-
diabetics.19,20
No case of TVR was seen in this subgroup analysis. Before
the stent era, the rate of coronary restenosis was higher with
balloon angioplasty alone in diabetic compared with non-
diabetic patients (50e62% vs 25e35%).19 The development of
bare metal stents (BMS) and more recently of drug-eluting
stents (DES) has changed dramatically the prognosis of PCI in
this population.
The superior efficacy of DES compared with BMS to
improve outcome and angiographic restenosis was of interest
in diabetic patients at particularly high risk of restenosis and
cardiovascular events. A major randomized trial ‘ISAR-DIA-
BETIC’ has been designed specifically to address diabetic pa-
tients.7,21 There was a clear efficacy of the limus stent inTable 6 e MACE.
Events n %
Death 01 0.2
MI 02 0.4
Re-PCI 00 00
Total MACE 03 0.62
Please cite this article in press as: Goyal BK, et al., A two year anal
all comers registry in India, Indian Heart Journal (2014), http://dxreducing both angiographic and clinical parameters of reste-
nosis in both insulin dependent and non-insulin dependent
diabetes mellitus. A meta-analysis comparing DES and BMS,
confirmed that the occurrence of major adverse cardiac
events (MACE) was highly reduced with DES from 19.9% to
10.1% (odds ratio (OR) 0.46, 95% confidence interval (CI) 0.41 to
0.52; p ¼ 0.001).13
The authors, however, point to a significant heterogeneity
between subgroups according to the type of DES (p ¼ 0.001):
MACE was 0.28 (95% CI 0.25e0.35) in the sirolimus group and
0.62 (95% CI 0.53e0.73) in the paclitaxel group (indirect com-
parison). The restenosis rate was also reduced with DES (from
31.7% to 10.5%) with a similar heterogeneity between the two
devices. The incidence of ST is lower than similar recent
registries. In this meta-analysis, a trend toward an increased
risk of non-Q wave myocardial infarction (MI) and stent
thrombosis was observed with paclitaxel. However, mortality,
Q wave MI and stent thrombosis rates were similar.20 In a
recent meta-analysis of head to head trials, reported the same
difference in favor of the limus eluting stent, although the risk
of death or MI was not significantly different between the two
DES.22
The DIABETES (Diabetes and Sirolimus-Eluting Stent) trial
specifically assessed the effects of a sirolimus-eluting stent
(SES) in DM. Notably, late loss at stent edges was similar in the
SES and BMS groups. This might be explained by relative drug
sparing at the edge of the stent, injury at the peri stent zone,
and geographic miss.21
The SIRTAX (Sirolimus-versus paclitaxel-eluting stents)
trial suggests that Sirolimus-eluting stent (SES) might be
preferred to paclitaxel-eluting stent (PES) for PCI in DM.23
1 year outcomes from the EVENT registry of diabetic
(n ¼ 256) versus non-diabetic (n ¼ 466) patients undergoing
multivessel PCI with DES at 1 year, all cause death, nonfatal
MI, and any revascularization procedure were equivalent be-
tween the diabetic and non-diabetic groups, specifically,
10.4% of the diabetics had an additional revascularization
procedure versus 6.4% in the non-diabetics, p ¼ 0.05.24
In the study of 4751 diabetic patients, the use of second
generation DES was associated with improved outcomes
compared with first generation DES mainly driven by lower
rates of ST and mortality.25
Results observed in our subgroup analysis, could be due to
unique combination of Biolimus A9 drug (which is 10 times
more lipophilic than its analogs), biodegradable polymer PLA
and technology of abluminal coating. These support favorableTable 7 e Stent thrombosis.
Stent thrombosis 01 Late probable
ysis of Diabetic subset ‘e-BioMatrix’ prospective, multicentric,
.doi.org/10.1016/j.ihj.2014.08.011
i n d i a n h e a r t j o u r n a l x x x ( 2 0 1 4 ) 1e6 5clinical outcomes of using BioMatrix stents as a suitable
alternative to contemporary DES during PCI in diabetic pa-
tients. Highlights like advanced stent design, highly lipophilic
Biolimus A9 drug, biodegradable polymer (PLA) and their
application on the abluminal side of the stent could be
responsible for such encouraging results of BioMatrix BES.
Interim report of the BioMatrix dedicated diabetic registry also
showed significantly lowered MACE rates.26 This subgroup
analysis has similar outcomes favoring use of BioMatrix DES
in diabetic patients.5. Study limitation
Since patients treated with other than Biolimus stents during
the index procedure was an exclusion criterion, no informa-
tion was collected on other DES. Secondly, this was not a
randomized study but a diabetic subgroup analysis from the
BioMatrix all comers registry.6. Conclusion
Though this subgroup study of the diabetic patients along
with additional risk factors like STEMI, CTO, bifurcation etc,
this next generation DES showed promising results. These
results which are similar to BioMatrix diabetic registry, con-
firms the sustained safety and efficacy profile of BioMatrix DES
(Biolimus A9-eluting stent) for the treatment of diabetic pa-
tients. These outcomes are possibly related to its specific
design alongwith abluminal coating of biodegradable polymer
and Biolimus A9 drug.Conflicts of interest
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